Related Experiment Video
Updated: Feb 6, 2026
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Current challenges in managing comorbid heart failure and COPD
J Alberto Neder1,2, Alcides Rocha2, Maria Clara N Alencar2
1a Laboratory of Clinical Exercise Physiology , Kingston Health Science Center & Queen's University , Kingston , Canada.
Insights
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) commonly coexist. Understanding their interactions is key to optimizing treatment and improving patient outcomes for this growing population.
Area of Science:
- Cardiology
- Pulmonology
- Internal Medicine
Background:
- Heart failure (HF) with reduced ejection fraction and chronic obstructive pulmonary disease (COPD) frequently coexist, especially in elderly patients.
- The rising prevalence of these conditions, coupled with increased life expectancy, positions overlapping HF-COPD as a significant future cause of morbidity and mortality.
- Understanding the complex interplay between these two diseases is crucial for effective management.
Purpose of the Study:
- To discuss the consequences of cardiopulmonary interactions on diagnostic tests in HF-COPD.
- To analyze the impact of each condition on the pharmacological treatment of the other.
- To outline tailored non-pharmacological treatments, such as rehabilitation, for patients with HF-COPD.
Main Methods:
- Review of current clinical and physiological constructs related to HF-COPD.
- Discussion of diagnostic challenges and treatment rationales arising from cardiopulmonary interactions.
- Comprehensive analysis of pharmacological and non-pharmacological treatment strategies.
Main Results:
- Cardiopulmonary interactions in HF-COPD present diagnostic and assessment challenges but offer a framework for treatment.
- The impact of HF on COPD treatment and vice versa requires careful consideration.
- Non-pharmacological interventions like rehabilitation can be specifically adapted for HF-COPD patients.
Conclusions:
- Integrated management strategies are essential for patients with coexisting HF and COPD.
- Future clinical trials should include a significant proportion of patients with these comorbidities.
- Multidisciplinary clinics are vital for reducing the burden of HF-COPD.
Introduction:
Heart failure (HF) with reduced ejection fraction and chronic obstructive pulmonary disease (COPD) frequently coexist, particularly in the elderly. Given their rising prevalence and the contemporary trend to longer life expectancy, overlapping HF-COPD will become a major cause of morbidity and mortality in the next decade. Areas covered: Drawing on current clinical and physiological constructs, the consequences of negative cardiopulmonary interactions on the interpretation of pulmonary function and cardiopulmonary exercise tests in HF-COPD are discussed. Although those interactions may create challenges for the diagnosis and assessment of disease stability, they provide a valuable conceptual framework to rationalize HF-COPD treatment. The impact of COPD or HF on the pharmacological treatment of HF or COPD, respectively, is then comprehensively discussed. Authors finalize by outlining how the non-pharmacological treatment (i.e. rehabilitation and exercise reconditioning) can be tailored to the specific needs of patients with HF-COPD. Expert commentary: Randomized clinical trials testing the efficacy and safety of new medications for HF or COPD should include a sizeable fraction of patients with these coexistent pathologies. Multidisciplinary clinics involving cardiologists and respirologists trained in both diseases (with access to unified cardiorespiratory rehabilitation programs) are paramount to decrease the humanitarian and social burden of HF-COPD.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:22Heart Failure VI: Adjunct Therapies